

22 November 2022  
EMA/896931/2022

## List of NCA's participating in the Simultaneous National Scientific Advice (SNSA) pilot phase 2

For SNSA requests/inquiries the contact details of all NCA's participating in the SNSA pilot phase 2 can be found in the list below:

No.	Country	Agency	Contact info	Leading/participating NCA	Observer Role
1	Austria	AGES/BASG	<a href="mailto:scientificadvice@basq.gv.at">scientificadvice@basq.gv.at</a> <a href="mailto:innovation@ages.at">innovation@ages.at</a>	X	
2	Belgium	FAMHP	<a href="mailto:innovationoffice@fagg-afmp.be">innovationoffice@fagg-afmp.be</a> <a href="mailto:sta-wta@fagg-afmps.be">sta-wta@fagg-afmps.be</a>	X	
3	Czechia	SUKL – Czech Republic	<a href="mailto:innovation@sukl.cz">innovation@sukl.cz</a>	X	
4	Denmark	DKMA	<a href="mailto:Nationalscientificadvice@dkma.dk">Nationalscientificadvice@dkma.dk</a> <a href="mailto:innovation@dkma.dk">innovation@dkma.dk</a>	X	
5	Finland	FIMEA	<a href="mailto:innovation.office@fimea.fi">innovation.office@fimea.fi</a>	X	
6	France	ANSM	<a href="mailto:innovation@ansm.sante.fr">innovation@ansm.sante.fr</a>	X	
7	Germany	PEI	<a href="mailto:innovation@pei.de">innovation@pei.de</a>	X	
8	Hungary	OGYEI	<a href="mailto:tanacsadas@oqyei.gov.hu">tanacsadas@oqyei.gov.hu</a>	X	
9	Ireland	HPRA	<a href="mailto:innovationoffice@hpра.ie">innovationoffice@hpра.ie</a> <a href="mailto:scientificadvice@hpра.ie">scientificadvice@hpра.ie</a>	X	
10	Italy	AIFA	<a href="mailto:Innovation.office@aifa.gov.it">Innovation.office@aifa.gov.it</a>		X
11	Netherlands	MEB	<a href="mailto:innovation@cbg-meb.nl">innovation@cbg-meb.nl</a>	X	
12	Netherlands	CCMO	<a href="mailto:ccmo@ccmo.nl">ccmo@ccmo.nl</a>		X
13	Norway	NOMA	<a href="mailto:Ask-us@legemiddelverket.no">Ask-us@legemiddelverket.no</a>	X	
14	Poland	URPL	<a href="mailto:snsa@urpl.gov.pl">snsa@urpl.gov.pl</a> <a href="mailto:innowacjaPL@urpl.gov.pl">innowacjaPL@urpl.gov.pl</a>	X	
15	Portugal	INFARMED	<a href="mailto:garc@infarmed.pt">garc@infarmed.pt</a>	X	
16	Sweden	MPA	<a href="mailto:innovationoffice@lakemedelsverket.se">innovationoffice@lakemedelsverket.se</a> <a href="mailto:RIC@lakemedelsverket.se">RIC@lakemedelsverket.se</a>	X	
17	Spain	AEMPS	<a href="mailto:ascina@aemps.es">ascina@aemps.es</a> <a href="mailto:innov_spain@aemps.es">innov_spain@aemps.es</a>	X	

- (11) The Medicines Evaluation Board (MEB) is the Dutch competent authority responsible for assessing medicinal products (eg. scientific advice, marketing authorisation applications) and for monitoring the risk of medicines for human use, and for promoting the proper use of medicines. The MEB is however not responsible for the evaluation of clinical trials applications.
- (12) The Central Committee on Research Involving Human Subjects (CCMO) is the Dutch competent authority responsible for the evaluation of clinical trial applications.

**Remark:**

The NCA's listed above have agreed to actively participate in the handling of the incoming SNSA pilots either as coordinating / participating NCA or as observer. In either case, the involvement is on a voluntary, opting-in basis (i.e. pending the available expertise and capacity at NCA level). The list of NCA's participating in the SNSA pilot phase 2 is subject to change and will be regularly updated as additional NCA's may consider participating in the course of the pilot.